10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In recent weeks, stellar results from Merck & Co and from Pfizer have elevated expectations for the potential of antivirals to treat coronavirus disease. 17 November 2021
China’s biotech industry enjoyed significant growth in the past several years, but major bottlenecks are looming as Chinese biotechs aims for a global expansion, said speakers at the two-day event Chinatrials on November 11 in Shanghai. 17 November 2021
US pharma giant Pfizer said yesterday it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. 17 November 2021
US biotech Biogen surprised industry watchers, with the announcement that Alfred (Al) Sandrock Jr, head of research and development, will retire from the company effective December 31, 2021. 17 November 2021
More than 20,000 strokes and 5,000 deaths could be averted after NHS England struck new agreements to expand life-saving blood thinning drugs, chief executive Amanda Pritchard announced yesterday. 17 November 2021
The Institute for Clinical and Economic Review (ICER) regularly calls out drugmakers in certain therapy areas for introducing drugs to the market at prices that exceed its estimates of what they are worth. 16 November 2021
US pharma giant Pfizer has had enormous success with its COVID-19 vaccine Comirnaty, developed and marketed with Germany’s BioNTech, and is now turning to its oral antiviral to treat the coronavirus infection, Paxlovid (ritonavir), for which it released stunning trial results last week. 16 November 2021
In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, developing medicines, and supply chain interruptions. 16 November 2021
Czech immuno-oncology company SOTIO Biotech, which is owned by PPF Group, today announced an exclusive, target-specific license and option agreement with South Korean biotech LegoChem Biosciences, a company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs). 16 November 2021
While injectable PCSK9 inhibitors have long promised an effective way to lower LDL cholesterol levels, relatively low uptake has been blamed on high prices and a burdensome mode of administration. 16 November 2021
The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in China. 16 November 2021
US DNA synthesis firm Twist Bioscience has launched Revelar Biotherapeutics, an independently operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by its Twist Biopharma division, that neutralizes all known variants of concern of the SARS-CoV-2 virus in pre-clinical studies. 16 November 2021
The Russian drugmaker R-Pharm plans to produce Sputnik V vaccine in the European Union and has received a three-year loan of 50 million ($57 million) to expand the company's production in Illertissen, Germany. 16 November 2021
German pharma and life sciences firm Merck KGaA and the Pediatric Praziquantel Consortium today announced that the pivotal Phase III trial for arpraziquantel, a potential new treatment option for the neglected tropical disease schistosomiasis, has met the primary endpoint of clinical cure in children three months to six years of age. 16 November 2021
Dutch fatty acid expert NorthSea Therapeutics has presented positive interim data from a Phase IIb study of its non-alcoholic steatohepatitis (NASH) candidate, icosabutate. 16 November 2021
German drugmaker STADA Arzneimittel plans to continue an active development in the Russian pharmaceutical market in the coming years, considering it as one of the most promising for its further growth, reports The Pharma Letter’s local correspondent. 16 November 2021
A set of guidelines that will provide a well-defined framework and guiding principle to facilitate sharing of biological information and data generated by research groups in India has been released by the government. 16 November 2021
Australian off-the-shelf cell therapy specialist Mesoblast saw its shares gain nearly 12% to A$1.90 today, as it released positive new results from the landmark Phase III study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). 15 November 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024